Mantle cell lymphoma shows three morphological evolutions of classical, intermediate, and aggressive forms, which occur in parallel with increased labeling index of cyclin D1 and Ki-67

Cancer Science

Volumn 101, Issue 3, 2010, Pages 806-814

  Kimura, Yoshizo ^a   Sato, Kensaku ^a   Arakawa, Fumiko ^a   Karube, Kennosuke ^a   Nomura, Yuko ^a,d   Shimizu, Kei ^e   Aoki, Ryosuke ^a   Hashikawa, Keiko ^a   Yoshida, Shiro ^a   Kiyasu, Junichi ^a   Takeuchi, Masanori ^a   Nino, Daisuke ^a   Sugita, Yasuo ^a   Morito, Toshiaki ^b   Yoshino, Tadashi ^b   Nakamura, Shigeo ^c   Kikuchi, Masahiro ^f   Ohshima, Koichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d FUKUOKA UNIVERSITY   (Japan)

^e YAMAGATA UNIVERSITY   (Japan)

^f Murakami Karindoh Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MOLECULAR EVOLUTION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STRUCTURE ANALYSIS; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; CYCLIN D1; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KI-67 ANTIGEN; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77949599241     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01433.x     Document Type: Article

References (42)

1. Bertoni F, Zucca E, Cotter FE. Molecular basis of mantle cell lymphoma. Br J Haematol 2004, 124:130-40.
2. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007, 7:750-62.
3. Bernard M, Gressin R, Lefrere F. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia 2001, 15:1785-91.
4. Weisenburger DD, Vose JM, Greiner TC. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 2000, 64:190-6.
5. Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997, 89:2067-78.
6. Tiemann M, Schrader C, Klapper W. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005, 131:29-38.
7. Yatabe Y, Suzuki R, Matsuno Y. Morphological spectrum of cyclin D1-positive mantle cell lymphoma: study of 168 cases. Pathol Int 2001, 51:747-61.
8. World Health Organization Classification of Tumors 2001, Swerdlow SH BIsaacson PIMuller-Hermelink HKNathwani BNPiris MAHarris NL. ed, Lyon, France, IARC Press
9. World Health Organization classification of Tumors 2008, Swerdlow EC MS SHMuller-Hermelink HK. ed, Lyon, France, IARC Press
10. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999, 36:115-27.
11. Yin CC, Medeiros LJ, Cromwell CC. Sequence analysis proves clonal identity in five patients with typical and blastoid mantle cell lymphoma. Mod Pathol 2007, 20:1-7.
12. Duggan MJ, Weisenburger DD, Ye YL. Mantle zone lymphoma. A clinicopathologic study of 22 cases. Cancer 1990, 66:522-9.
13. Laszlo T, Matolcsy A. Blastic transformation of mantle cell lymphoma: genetic evidence for a clonal link between the two stages of the tumour. Histopathology 1999, 35:355-9.
14. Laszlo T, Nagy M, Kelenyi G, Matolcsy A. Immunoglobulin V(H) gene mutational analysis suggests that blastic variant of mantle cell lymphoma derives from different stages of B-cell maturation. Leuk Res 2000, 24:27-31.
15. Kaleem Z, Wakoff AR, Smith RP, Hess JL. Blastic transformation of mantle cell lymphoma. Arch Pathol Lab Med 1996, 120:577-80.
16. Majlis A, Pugh WC, Rodriguez MA, Benedict WF, Cabanillas F. Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants. J Clin Oncol 1997, 15:1664-71.
17. Leitch HA, Gascoyne RD, Chhanabhai M, Voss NJ, Klasa R, Connors JM. Limited-stage mantle-cell lymphoma. Ann Oncol 2003, 14:1555-61.
18. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13:1501-12.
19. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001, 1:222-31.
20. Izban KF, Alkan S, Singleton TP, Hsi ED. Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in mantle cell lymphoma. Arch Pathol Lab Med 2000, 124:1457-62.
21. Chilosi M, Doglioni C, Magalini A. p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin's lymphomas: a potential marker of p53 tumor-suppressor gene function. Blood 1996, 88:4012-20.
22. Pinyol M, Hernandez L, Cazorla M. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 1997, 89:272-80.
23. Letestu R, Ugo V, Valensi F. Prognostic impact of p27KIP1 expression in cyclin D1 positive lymphoproliferative disorders. Leukemia 2004, 18:953-61.
24. Quintanilla-Martinez L, Thieblemont C, Fend F. Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor. Am J Pathol 1998, 153:175-82.
25. Chiarle R, Budel LM, Skolnik J. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 2000, 95:619-26.
26. Zoldan MC, Inghirami G, Masuda Y. Large-cell variants of mantle cell lymphoma: cytologic characteristics and p53 anomalies may predict poor outcome. Br J Haematol 1996, 93:475-86.
27. Moller MB, Gerdes AM, Skjodt K, Mortensen LS, Pedersen NT. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma. Clin Cancer Res 1999, 5:1085-91.
28. Moller MB, Nielsen O, Pedersen NT. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma. Histopathology 2002, 41:322-30.
29. Yatabe Y, Suzuki R, Tobinai K. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 2000, 95:2253-61.
30. Ohshima KS, Suzumiya J, Kawasaki C, Kanda M, Kikuchi M. Cytoplasmic cytokines in lymphoproliferative disorders: multiple cytokine production in angioimmunoblastic lymphadenopathy with dysproteinemia. Leuk Lymphoma 2000, 38:541-5.
31. Martin-Subero JI, Harder L, Gesk S. Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci. Int J Cancer 2002, 98:470-4.
32. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987-94.
33. Hosokawa Y, Gadd M, Smith AP, Koerner FC, Schmidt EV, Arnold A. Cyclin D1 (PRAD1) alternative transcript b: full-length cDNA cloning and expression in breast cancers. Cancer Lett 1997, 113:123-30.
34. Rosenwald A, Wright G, Wiestner A. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3:185-97.
35. Wiestner A, Tehrani M, Chiorazzi M. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood 2007, 109:4599-606.
36. Ott MM, Bartkova J, Bartek J. Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity. Blood 1997, 90:3154-9.
37. Shakir R, Ngo N, Naresh KN. Correlation of cyclin D1 transcript levels, transcript type and protein expression with proliferation and histology among mantle cell lymphoma. J Clin Pathol 2008, 61:920-7.
38. Sander B, Flygare J, Porwit-Macdonald A. Mantle cell lymphomas with low levels of cyclin D1 long mRNA transcripts are highly proliferative and can be discriminated by elevated cyclin A2 and cyclin B1. Int J Cancer 2005, 117:418-30.
39. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995, 82:675-84.
40. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994, 78:67-74.
41. Zeng YX, el-Deiry WS. Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene 1996, 12:1557-64.
42. Howard OM, Gribben JG, Neuberg DS. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002, 20:1288-94.